Gina Z. D'Amato, MD

home / authors / gina-z-damato-md

Articles

Gina Z. D’Amato, MD

Dr. D’Amato on Optimizing Treatment for Patients With Desmoid Tumors

Gina Z. D'Amato, MD
November 18th 2021

Gina Z. D’Amato, MD, discusses optimizing treatment for patients with desmoid tumors.

Read More

Gina Z. D'Amato, MD, of Sylvester Comprehensive Cancer Center

Dr. D’Amato on the Importance of Multidisciplinary Care in Sarcoma

Gina Z. D'Amato, MD
October 30th 2020

Gina Z. D'Amato, MD, discusses the importance of multidisciplinary care in sarcoma.

Read More

Gina Z. D'Amato, MD

Dr. D’Amato on the Limitations of Liquid Biopsy in Sarcoma

Gina Z. D'Amato, MD
October 21st 2020

Gina Z. D'Amato, MD, discusses the limitations of liquid biopsy in sarcoma.

Read More

Gina Z. D'Amato, MD

Dr. D’Amato on the Diminishing Role of Chemotherapy in Sarcoma

Gina Z. D'Amato, MD
October 9th 2020

Gina Z. D'Amato, MD, discusses the diminishing role of chemotherapy in sarcoma.

Read More

Dr. D'Amato on the Utility of NGS in Stage I, II, and III Sarcoma

Dr. D'Amato on the Utility of NGS in Stage I, II, and III Sarcoma

Gina Z. D'Amato, MD
August 19th 2020

Gina Z. D'Amato, MD, discusses the utility of next-generation sequencing in patients with stage I, II, or III sarcoma.

Read More

Dr. D'Amato on the Emerging Role of Next-Generation Sequencing in Sarcoma

Dr. D'Amato on the Emerging Role of Next-Generation Sequencing in Sarcoma

Gina Z. D'Amato, MD
April 11th 2020

Gina Z. D'Amato, MD, discusses the emerging role of next-generation sequencing in sarcoma.

Read More

Latest Updated Articles

Sarwish Rafiq, PhD
Published: July 9th 2024 | Updated: July 10th 2024
Dr Rafiq on Novel Strategies for CAR T-Cell Engineering in Solid Tumors
Jens Hoeppner, FAChirg, FACS, MD
Published: June 2nd 2024 | Updated: June 3rd 2024
Perioperative Chemotherapy Prolongs OS vs Neoadjuvant Chemoradiation in Esophageal Cancer
Julia Rotow, MD, clinical director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School
Published: July 25th 2024 | Updated: July 27th 2024
Dr Rotow on the Impact of Biomarker Testing on NSCLC Treatment Outcomes
Joshua K. Sabari, MD, assistant professor, Department of Medicine, New York University Grossman School of Medicine; director, High Reliability Organization Initiatives, Perlmutter Cancer Center
Published: July 25th 2024 | Updated: July 27th 2024
Dr Sabari on Barriers to Biomarker Testing in NSCLC
5 KOLs are featured in this series.
Published: July 18th 2024 | Updated: July 27th 2024
Treatment Considerations and Patient Selection for CAR T-cell Therapy in R/R ALL
5 KOLs are featured in this series.
Published: July 18th 2024 | Updated: July 27th 2024
Expert Insights on ZUMA-3 Data Updates: 4-Year Follow-up and Real World Data